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Relationship among catheter insertions, vascular access infec-
tions, and anemia management in hemodialysis patients.
Background. Arteriovenous fistulas are the recommended
permanent vascular access (VA) for chronic hemodialysis.
However, in the United States most patients begin chronic
hemodialysis with a catheter. Recent data suggest that VA type
contributes to recombinant human erythropoietin (rHuEPO)
resistance. We examined catheter insertions, VA infections, and
anemia management in Medicare, rHuEPO-treated, chronic
hemodialysis patients.
Methods. We compared hemoglobin values and rHuEPO and
intravenous iron dosing with concurrent catheter insertions and
VA infections in 186,348 period-prevalent patients in 2000. We
studied anemia management after catheter insertions and VA
infections in 67,410 incident patients from 1997 to 1999. Multiple
linear regression models examined follow-up hemoglobin and
rHuEPO dose per week (rHuEPO/wk) by numbers of catheter
insertions and hospitalizations for VA infection.
Results. In the prevalent cohort, increasing temporary and
permanent catheter insertions and VA infections were associ-
ated with slightly lower hemoglobin, higher rHuEPO doses, and
higher intravenous iron doses. In the incident cohort, compared
to patients with no VA infections or no catheter insertions (tem-
porary or permanent), respectively, patients with 2+ VA infec-
tions or 2+ catheter insertions had 0.12 g/dL and 0.06 g/dL lower
mean hemoglobin (P = 0.0028 and P < 0.0001), and 25.7% and
12.2% higher mean rHuEPO/wk (P < 0.0001).
Conclusion. Higher rHuEPO doses may be required to main-
tain similar or slightly lower mean hemoglobin values among
chronic hemodialysis patients with higher numbers of catheter
insertions and VA infections, compared to patients without any.
Arteriovenous (AV) fistulas are considered the perma-
nent vascular access (VA) of choice for chronic hemodial-
ysis because they are associated with higher patency rates
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and lower rates of infection compared to polytetrafluo-
roethylene (PTFE) grafts [1]. However, in the United
States (U.S.), most patients begin chronic hemodialysis
with a catheter, and PTFE grafts are more common than
AV fistulas. Catheters are not recommended as perma-
nent VA because of their increased risk of luminal throm-
bosis [2, 3] and infection [4–6], lower delivered dose of
dialysis due to unreliable blood flow [7–10], risk of cen-
tral venous stenosis [11], shorter expected use life [12],
and cosmetic concerns [1]. Recent studies also suggest
that catheter use is associated with an increased risk of
all-cause and infection-related mortality in both incident
and prevalent hemodialysis patients [10, 13].
Scant data are available regarding the effect that type
of VA used for chronic hemodialysis has on anemia
management. In a small cohort of Spanish hemodialysis
patients with no recognizable causes of resistance
to recombinant human erythropoietin (rHuEPO),
consistent use of PTFE grafts was associated with signifi-
cantly higher rHuEPO doses to achieve the target hema-
tocrit value compared to AV fistulas [14]. Given the high
prevalence of PTFE grafts and catheters among patients
undergoing chronic hemodialysis in the U.S. [15, 16], we
hypothesized that catheter insertions and VA infections
may be important contributors to rHuEPO resistance,
and, consequently, to the overall utilization of rHuEPO
therapy in these patients.
In this study, we examined the effect of catheter in-
sertions and VA infections on anemia management in a
large cohort of U.S. chronic hemodialysis patients.
METHODS
Overview
Associations among anemia management, catheter in-
sertions, and VA infections were described in 2 patient
cohorts: period-prevalent and incident hemodialysis pa-
tients. Both cohorts were used to obtain a broad view of
associations in 2 diverse patient groups. In the incident
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cohort, we also performed a regression analysis of follow-
up hemoglobin and rHuEPO dose, adjusting for entry-
period characteristics. The incident cohort was selected
for this regression because it contained patients with sim-
ilar time on dialysis. This may result in less confounding
than with a prevalent cohort, which has a mixture of pa-
tients with varying lengths of time on dialysis.
Concurrent anemia management, catheter insertions,
and VA infections in period-prevalent hemodialysis
patients
Data sources and patient population. We studied
period-prevalent Medicare hemodialysis patients from
the year 2000. The start of the follow-up period was de-
fined as follows: January 1 for point-prevalent patients
who were prevalent on January 1, 2000, and whose first
end-stage renal disease (ESRD) service date was at least
90 days before January 1; and day 91 of ESRD for in-
cident patients who reached day 91 of ESRD between
January 1 and December 31, 2000. The follow-up period
started after day 90 due to incomplete claims in the first
90 days after initiation of dialysis. Patients were followed
until the earliest date of death, modality change, loss to
follow-up, or December 31, 2000. Patients with Medicare
as a secondary payer, with coverage from a health main-
tenance organization (HMO), or with dialysis payment
amounts less than $675 per month were excluded on the
basis of incomplete Medicare claims [17].
Patient demographic data (including age, gender, race,
and primary cause of ESRD) were obtained from the
Identification and Medical Evidence portions of the Re-
nal Beneficiary Utilization System of the Centers for
Medicare & Medicaid Services. Data on hematocrit
value, rHuEPO dose, and intravenous (IV) iron use
were obtained from Medicare institutional outpatient
claims. Included rHuEPO-treated patients had at least
one rHuEPO claim during the year. Compared to pre-
vious years, Medicare billing for IV iron changed in the
year 2000, with billing done by dosing increments (e.g.,
50-mg injections of iron dextran), rather than number of
vials. Consequently, the billing data included claims for
both vials and doses. For patients in the year 2000, we
considered two 50-mg doses to equal one 100-mg vial. Of
the IV iron billed in 2000, 92% was for iron dextran, and
8% was for ferric gluconate.
Data on catheter insertions were drawn from Medicare
Part B physician/supplier claims; data on hospitalizations
for VA infection were taken from Part A institutional in-
patient claims. Event information was obtained from the
following Physicians’ Current Procedural Terminology
(CPT) and International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) codes: tem-
porary catheter insertions, CPT codes 36489, 36491, and
36800; permanent catheter insertions, CPT code 36533;
and VA infection, ICD-9-CM principal diagnosis code
996.62. Additional methods excluded catheters used for
purposes other than dialysis, and excluded patients with
any chemotherapy or parenteral nutrition claims during
the year [17]. Catheter insertions indicated by Health-
care Common Procedure Coding System (HCPCS) codes
36489, 36491, and 36533 were included only if they were
associated with a line-level or claim-level principal diag-
nosis code related to dialysis or kidney failure.
Analysis. Hematocrit values were used to calculate esti-
mated hemoglobin values because complete hemoglobin
data are unavailable in the Medicare claims. For each pa-
tient, each hematocrit value during the year was divided
by three; then, these estimated hemoglobin values were
averaged to obtain the mean hemoglobin value. Mean
rHuEPO dose per week (rHuEPO/wk) was calculated as
total rHuEPO received divided by total outpatient weeks.
Outpatient weeks were calculated as the total number of
weeks of follow-up after subtracting inpatient hospital
days because outpatient rHuEPO claims are not gener-
ated during hospitalizations. Patients were grouped ac-
cording to number (0, 1, or 2+, where 2+ indicates ≥2)
of catheter insertions (temporary or permanent) and hos-
pitalizations for VA infection during the year, and the fol-
lowing were computed for each group: mean hemoglobin,
mean rHuEPO/wk, and mean IV iron vials per month.
The Wilcoxon rank-sum test compared mean values be-
tween groups (0 vs. 1 and 0 vs. 2+ catheter insertions and
hospitalizations for VA infection).
Anemia management after catheter insertion and VA
infection in incident hemodialysis patients
Data sources and patient population. We evaluated
adult incident Medicare hemodialysis patients who were
treated between January 1, 1997, and December 31, 1999.
Because Medicare data may be incomplete in the 90 days
following the first ESRD service date, included patients
survived those 90 days plus 6-month entry and 6-month
follow-up periods. Inclusion criteria followed those used
in the prevalent analyses, with these additional require-
ments: included patients had at least three rHuEPO
claims during follow-up, had a valid hematocrit measure-
ment at initiation of dialysis, were at least 20 years old,
and had complete age and gender data.
Sources for demographic data, as well as for hema-
tocrit, rHuEPO, and IV iron, were identical to those
described for the prevalent patient analysis. For each pa-
tient, the total number of entry-period months (range, 0
to 6 total months) with any IV iron claim was determined.
The data sources and definitions of hospitalization for VA
infection and temporary or permanent catheter insertion
(characterized during the entry period) also replicated
those described for prevalent patients. A hematocrit mea-
surement at initiation of dialysis was obtained for each
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patient from the Medical Evidence form, and hemoglobin
at initiation was estimated by dividing this value by three.
The number of hospital days and blood transfusions
during the 6-month entry period were obtained from
Medicare Part A and B claims files [18]. Patients were
characterized by number of total hospital days during the
entry period, and by number of non-VA hospital days (all
hospital days except those having a principal ICD-9-CM
diagnosis code 996.62, for VA infection). Comorbid con-
ditions were determined from Part A and B Medicare
claims during the 6-month entry period using CPT and
ICD-9-CM codes, as previously described [19].
Also, because VA infections may occur in both inpa-
tient and outpatient settings, an additional indicator of
“any VA infection” used data from any institutional (in-
patient, outpatient, home health, and skilled nursing) or
physician/supplier Medicare claim. This indicator classi-
fied patients as with or without any VA infection (1+
or 0).
Analysis. During the follow-up period, mean
hemoglobin, mean rHuEPO/wk, and number of months
with IV iron were calculated for each patient; mean
hemoglobin and mean rHuEPO/wk were computed
as previously described. Patients were categorized by
number (0, 1, or 2+) of entry-period hospitalizations
for VA infection and entry-period catheter insertions
(temporary or permanent). The Wilcoxon rank-sum test
compared mean hemoglobin, mean rHuEPO/wk, and
mean number of months with IV iron between groups (0
vs. 1 and 0 vs. 2+ catheter insertions and hospitalizations
for VA infection).
Using multiple linear regression models, hemoglobin
and rHuEPO/wk during follow-up were compared
among groups by entry-period catheter insertions and
VA infections. The independent predictors included inci-
dent year, age (20–44, 45–64, 65–74, and 75+ years), race
(white, black, other), gender, primary cause of ESRD
(diabetes and nondiabetes), hemoglobin at initiation of
dialysis, number of months with IV iron during the en-
try period, number of blood transfusions, and comor-
bid conditions (atherosclerotic heart disease, congestive
heart failure, other cardiac disease, peripheral vascular
disease, cerebrovascular accident/transient ischemic at-
tack, cancer, chronic obstructive pulmonary disease, and
gastrointestinal disease with bleeding). Because catheter
insertions were correlated with VA infections, to reduce
multicollinearity, these two predictors were not included
in the same model. Therefore, two multiple linear regres-
sion models were used with follow-up hemoglobin as the
dependent variable, including the independent predictors
listed above, in addition to the following predictors dur-
ing the entry period: model 1, total hospital days (0, 1–4,
5–12, and 13+) and catheter insertions (0, 1, and 2+);
and model 2, non-VA hospital days (0, 1–4, 5–12, and
13+) and hospitalizations for VA infection (0, 1, and 2+).
To assess rHuEPO/wk during follow-up, models 1 and 2
were repeated using natural logarithmically transformed
rHuEPO/wk as the dependent variable. To reduce mul-
ticollinearity, non-VA hospital days (rather than total
hospital days) were included in the models with VA infec-
tions. Also, model 2 was repeated using the indicator for
any VA infection (0 and 1+) rather than hospitalization
for VA infection.
Assumptions of linear regression were checked by ex-
amining residuals from the data fitted to the model. The
variance inflation factor and correlation matrix suggested
that multicollinearity among independent variables was
not a problem. The patient-level data were trimmed to
improve normality: the lower 0.25% and upper 0.25%
of mean hemoglobin and lower 0.25% and upper 0.25%
of mean rHuEPO/wk. A natural log transformation of
rHuEPO/wk was used to satisfy the normality assump-
tion of linear regression [20]. The modified Levene test
[21] was used to test for nonconstant variance (het-
eroscedasticity). Significant heteroscedasticity was found
only in the models with hemoglobin as the dependent
variable. Weighted least-squares regression was used for
the hemoglobin models as a remedial measure for non-
constant variance. Consistent results obtained from the
weighted and ordinary-least-squares regression models
supported use of the ordinary-least-squares results.
RESULTS
Concurrent anemia management, catheter insertions,
and VA infections in period-prevalent hemodialysis
patients
The study included 186,348 rHuEPO-treated prevalent
patients; Table 1 displays their characteristics. Of these,
76.4% had mean hemoglobin ≥11g/dL, and 80.7% were
treated with IV iron. Increasing numbers of temporary
catheter insertions, permanent catheter insertions, and
hospitalizations for VA infection were associated
with decreasing mean hemoglobin, increasing mean
rHuEPO/wk, and increasing mean IV iron vials per
month (Fig. 1). Among patients with 2+ compared
to no catheter insertions, mean values of hemoglobin,
rHuEPO/wk, and IV iron vials per month were 0.35 g/dL
lower, 4987 units higher, and 0.22 vials higher (P <
0.0001), respectively. Similarly, among patients with 2+
compared to no hospitalizations for VA infection, respec-
tive values were 0.46 g/dL lower, 6789 units higher, and
0.24 vials higher (P < 0.0001). Comparisons among pa-
tients with one compared to no catheter insertions and
hospitalizations for VA infection also were statistically
significant (P < 0.0001; see Fig. 1 for mean values). Sim-
ilar results were found when temporary and permanent
catheters were analyzed separately (results not shown).
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Table 1. Characteristics of prevalent Medicare hemodialysis patients
in 2000a
Characteristic N %
All patients 186,348 100.0
Age years
0–44 27,772 14.9
45–64 61,852 33.2
65–74 51,974 27.9
75+ 44,730 24.0
Missing 20 0.0
Gender
Female 90,598 48.6
Male 95,750 51.4
Race
White 99,549 53.4
Black 74,661 40.1
Native American 3502 1.9
Asian 6122 3.3
Other/missing 2514 1.3
Primary cause of ESRD
Diabetes 75,948 40.8
Hypertension 54,102 29.0
Glomerulonephritis 20,790 11.2
Other/missing 35,508 19.1
Mean hemoglobin g/dL
<10.0 11,764 6.3
10.0–10.9 32,292 17.3
11.0–11.9 92,346 49.6
12.0–12.9 41,678 22.4
13.0+ 8268 4.4
Intravenous iron-treated 150,342 80.7
ESRD, end-stage renal disease; rHuEPO, recombinant human erythropoietin.
aIncludes rHuEPO-treated patients with no chemotherapy or parenteral
nutrition claims during the year.
Anemia management after catheter insertion and VA
infection in incident hemodialysis patients
The study included 67,410 incident Medicare
hemodialysis patients; Table 2 displays their char-
acteristics. Mean age was 65 years, 50.5% were male,
59.6% were white, 47.6% had diabetes as primary cause
of ESRD, mean hemoglobin at initiation was 9.5 g/dL,
46.6% had at least one hospital day, 44.8% had at
least one non-VA hospital day, 5.0% had at least one
hospitalization for VA infection, 82.8% had at least one
entry-period month with IV iron, 4.7% had at least one
blood transfusion, and 19.7% had at least one catheter
insertion.
As in the prevalent cohort, increasing numbers of
entry-period catheter insertions or hospitalizations for
VA infection were associated with slightly decreased
mean hemoglobin, increased mean rHuEPO/wk, and in-
consistently increased mean number of months with IV
iron during follow-up (see Fig. 2 for mean values; P <
0.0001 for all comparisons, except for mean number of
months with IV iron between patients with 2+ catheter
insertions and those with none, for which the P value was
0.11).
Regression analyses showed that higher numbers of
catheter insertions and hospitalizations for VA infection
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Fig. 1. Mean hemoglobin (A), mean rHuEPO dose/wk (B), and mean
monthly vials of IV iron (C) by number of catheter insertions (tempo-
rary or permanent) and hospitalizations for vascular access (VA) in-
fection during 2000. Includes prevalent rHuEPO-treated hemodialysis
patients in 2000.
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Table 2. Characteristics of 1997–1999 (combined) incident Medicare
hemodialysis patientsa
Characteristic N %
All patients 67,410 100.0
Incident year
1997 21,014 31.2
1998 22,860 33.9
1999 23,536 34.9
Age years
20–44 7138 10.6
45–64 18,341 27.2
65–74 23,452 34.8
75+ 18,479 27.4
Gender
Female 33,363 49.5
Male 34,047 50.5
Race
White 40,210 59.6
Black 23,059 34.2
Other/missing 4141 6.1
Primary cause of ESRD
Diabetes 32,085 47.6
Nondiabetes 35,325 52.4
Hemoglobin at initiation g/dL
<9.0 26,196 38.9
9.0–9.9 16,274 24.1
10.0–10.9 12,756 18.9
11.0–11.9 7216 10.7
12+ 4968 7.4
Total hospital days
0 35,996 53.4
1–4 11,610 17.2
5–12 10,456 15.5
13+ 9348 13.9
Non-VA hospital days
0 37,216 55.2
1–4 11,696 17.4
5–12 9947 14.8
13+ 8551 12.7
Hospitalizations for VA infection
0 64,010 95.0
1 2967 4.4
2+ 433 0.6
Any VA infection (from any data source)
0 52,793 78.3
1+ 14,617 21.7
No. of entry-period months with IV iron
0 11,583 17.2
1–4 31,103 46.1
5–6 24,724 36.7
Blood transfusions
0 64,264 95.3
1+ 3146 4.7
Temporary catheter insertions
0 58,020 86.1
1 6100 9.0
2+ 3290 4.9
Permanent catheter insertions
0 61,338 91.0
1 4794 7.1
2+ 1278 1.9
Catheter insertions (temporary or permanent)
0 54,101 80.3
1 8041 11.9
2+ 5268 7.8
Comorbid conditions
ASHD 39,885 59.2
CHF 43,421 64.4
Other cardiac disease 48,440 71.9
PVD 38,907 57.7
CVA/TIA 22,889 34.0
Cancer 14,484 21.5
COPD 20,361 30.2
GI disease 16,700 24.8
Liver disease 20,120 29.8
Abbreviations are: ASHD, atherosclerotic heart disease; CHF, congestive heart
failure; COPD, chronic obstructive pulmonary disease; CVA/TIA, cerebrovascular
accident/transient ischemic attack; ESRD, end-stage renal disease; GI, gastrointestinal;
IV, intravenous; PVD, peripheral vascular disease; rHuEPO, recombinant human
erythropoietin; VA, vascular access.
aIncludes rHuEPO-treated patients with no chemotherapy or parenteral nutrition
claims.
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Fig. 2. Mean hemoglobin (A), mean rHuEPO dose/wk (B), and mean
number of months with IV iron during 6-month follow-up (C), by num-
ber of entry-period catheter insertions (temporary or permanent) and
hospitalizations for vascular access (VA) infection. Includes 1997 to
1999 incident rHuEPO-treated hemodialysis patients.
were associated with slightly, yet significantly, lower mean
hemoglobin and significantly higher mean rHuEPO/wk
after controlling for other factors (Table 3). Compared
to those with no hospitalizations for VA infection, pa-
tients with 1 and those with 2+ VA infections had, re-
spectively, 0.07 and 0.12 g/dL lower mean hemoglobin
(P < 0.0001 and P = 0.0028), and 12.9% and 25.7% higher
mean rHuEPO/wk (P < 0.0001). Compared to patients
with no catheter insertions, patients with 1 and those
with 2+ catheter insertions had, respectively, similar and
0.06 g/dL lower mean hemoglobin (P = 0.9544 and P <
0.0001), and 6.9% and 12.2% higher mean rHuEPO/wk
(P < 0.0001). Also, compared to patients without any VA
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Table 3. Differences in mean hemoglobin and rHuEPO dose/wk from reference groups in 1997 to 1999 incident Medicare hemodialysis patientsa
Mean hemoglobin rHuEPO dose/wk
Characteristic difference g/dL P value difference % P value
Hospitalizations for VA infection
1 −0.07 <0.0001 12.9 <0.0001
2+ −0.12 0.0028 25.7 <0.0001
Any VA infection (from any data source)
1+ −0.03 0.0002 6.7 <0.0001
Catheter insertions (temporary or permanent)
1 0.00 0.9544 6.9 <0.0001
2+ −0.06 <0.0001 12.2 <0.0001
Age years
45–64 0.09 <0.0001 2.1 0.0415
65–74 0.16 <0.0001 −5.7 <0.0001
75+ 0.21 <0.0001 −11.6 <0.0001
Race
Black −0.06 <0.0001 11.0 <0.0001
Other 0.03 0.0552 −5.6 <0.0001
Male 0.05 <0.0001 −4.7 <0.0001
Diabetes as primary cause of ESRD −0.01 0.2418 1.2 0.0340
Hemoglobin at initiation g/dL
<9.0 −0.17 <0.0001 25.9 <0.0001
9.0–9.9 −0.11 <0.0001 14.9 <0.0001
10.0–10.9 −0.06 <0.0001 5.9 <0.0001
12+ 0.04 0.0124 −4.6 0.0002
Incident year
1998 0.40 <0.0001 11.3 <0.0001
1999 0.55 <0.0001 13.8 <0.0001
Total hospital days
1–4 −0.04 0.0001 8.6 <0.0001
5–12 −0.04 <0.0001 14.7 <0.0001
13+ −0.07 <0.0001 24.8 <0.0001
No. of entry-period months with IV iron
1–4 0.18 <0.0001 −3.8 <0.0001
5–6 0.26 <0.0001 −4.9 <0.0001
1+ blood transfusions −0.19 <0.0001 27.6 <0.0001
Comorbid conditions
ASHD 0.01 0.1388 −0.3 0.6812
CHF −0.06 <0.0001 7.5 <0.0001
Other cardiac disease −0.04 <0.0001 4.1 <0.0001
PVD 0.00 0.5373 3.6 <0.0001
CVA/TIA 0.01 0.0721 −3.3 <0.0001
Cancer −0.06 <0.0001 8.9 <0.0001
COPD −0.02 0.0095 −0.1 0.9097
GI disease −0.08 <0.0001 9.0 <0.0001
Liver disease 0.05 <0.0001 1.5 0.0093
Abbreviations are: ASHD, atherosclerotic heart disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA/TIA, cerebrovascular
accident/transient ischemic attack; ESRD, end-stage renal disease; GI, gastrointestinal; IV, intravenous; PVD, peripheral vascular disease; rHuEPO, recombinant
human erythropoietin; VA, vascular access.
a Includes rHuEPO-treated patients with no chemotherapy or parenteral nutrition claims. Reference groups include no hospitalizations for VA infection, no VA
infection from any data source, no catheter insertions, age 20 to 44 years, white, female, nondiabetes, hemoglobin of 11.0 to 11.9 g/dL at initiation, incident year of 1997,
no hospital days, no IV iron use, no blood transfusions, and no comorbid conditions during the entry period.
infections (as recorded in any data source), patients with
1+ VA infection had 0.03 g/dL lower mean hemoglobin
(P = 0.0002) and 6.7% higher mean rHuEPO/wk (P <
0.0001). Results and P values for other independent pre-
dictors are displayed in Table 3, and were obtained from
the multiple linear regression models with predictors as
described for model 1 in the Methods section. These re-
sults included significantly higher mean hemoglobin and
lower rHuEPO/wk among patients with hemoglobin at
initiation of 12.0+ g/dL versus 11.0 to 11.9 g/dL, and
among patients with 1 to 4 or 5 to 6 versus those with
0 entry-period months with IV iron.
DISCUSSION
Our results demonstrate that higher numbers of
catheter insertions and hospitalizations for VA infec-
tion are associated with slightly lower hemoglobin val-
ues and higher weekly rHuEPO requirements in both
prevalent and incident dialysis patients. In multivariate
analyses that adjusted for some factors that can influence
hemoglobin values and/or rHuEPO requirements, such
as hospitalizations, comorbidity, blood transfusions, and
iron use, the differences in weekly rHuEPO requirements
were 26% and 12% higher among those with 2+ hos-
pitalizations for VA infection or 2+ catheter insertions,
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respectively, compared to those without any. These re-
sults indicate that considerably more rHuEPO is needed
to achieve the same or a slightly lower hemoglobin value
in these patients. Also, when VA infections were char-
acterized from any data source, rather than only from
hospitalizations, and patients with and without any VA
infections were compared, we still found clinically simi-
lar, yet significantly lower, mean hemoglobin values, and
7% higher weekly rHuEPO requirements.
Several mechanisms may account for the association
of higher numbers of catheter insertions with lower
hemoglobin values and higher weekly rHuEPO re-
quirements, including higher incidence of infection with
catheters [22–30], surgical inflammation due to concomi-
tant procedures for placement of a permanent VA [1],
and lower dialysis dose due to reduced blood flow with
catheters [7–10]. However, the literature regarding the ef-
fect of dialysis dose and type of membrane on rHuEPO
responsiveness is inconclusive [1]. Additional mecha-
nisms underlying the association include blood loss from
surgery or the catheter site, as well as clotted dialysis
circuits.
Regarding the association of higher numbers of VA in-
fections with lower hemoglobin values and higher weekly
rHuEPO requirements, it is well known that infections
induce an inflammatory state that can markedly impair
responsiveness to rHuEPO [31]. The mechanism underly-
ing the association appears to involve increased produc-
tion of inflammatory cytokines, such as tumor necrosis
factor, interleukin-1, and interferon-gamma [32, 33]. In
support of this hypothesis, two recent studies have shown
that an elevated C-reactive protein value, which often is
associated with infection and/or inflammation, predicts
rHuEPO resistance in patients undergoing dialysis [34,
35].
Our finding of an association between higher numbers
of catheter insertions and VA infections with increased
rHuEPO requirements has important clinical and eco-
nomic implications, particularly in view of the high preva-
lence of catheter use and synthetic graft placement for
chronic hemodialysis in the U.S. In the Wave 2 of the Dial-
ysis Morbidity and Mortality Study, among 1805 incident
patients in 1996, 65% began in-center chronic hemodial-
ysis with a catheter, 24% with a PTFE graft, and 11%
with an AV fistula [15]. Two months after the start of
hemodialysis, 32% of patients still had a catheter as their
primary access, 50% a PTFE graft, and 18% an AV fistula.
In the Dialysis Outcomes and Practice Patterns Study,
VA was compared in a random cohort of European and
U.S. incident and prevalent hemodialysis patients [16].
Among incident patients, 66% of European patients be-
gan chronic hemodialysis with an AV fistula, 2% with a
graft, and 31% with a catheter. In contrast, only 15% of
U.S. patients began hemodialysis with an AV fistula, 24%
with a graft, and 60% with a catheter. Among prevalent
patients, 80% of European patients had an AV fistula,
10% an AV graft, and 8% a catheter, whereas 24% of
U.S. patients had an AV fistula, 57% an AV graft, and
17% a catheter. These differences in VA might partially
explain why mean rHuEPO doses for European patients
undergoing chronic hemodialysis are lower than those
used in their U.S. counterparts [36].
The National Kidney Foundation’s Kidney Disease
Outcomes Quality Initiative (NKF-K/DOQI) Guidelines
recommend that 40% of prevalent chronic hemodialysis
patients should have an AV fistula (guideline 29), and that
less than 10% of chronic hemodialysis patients should
be maintained on catheters, defined as use of catheters
for more than three months in the absence of a matur-
ing access (guideline 30). The NKF-K/DOQI Guidelines
also recommend that primary AV fistulas should be con-
structed in at least 50% of all new kidney failure patients
[1]. Given the results of our study, implementation of
these guidelines may have the additional benefit of re-
ducing rHuEPO requirements and, consequently, cost,
which currently exceeds $1 billion in the U.S. [37].
Our results should be interpreted with awareness of
the following limitations. First, relationships are associa-
tions and do not show causality. Second, Medicare claims
provide complete data on catheter insertions only after
day 90 of dialysis. The exclusion of catheter insertions in
the first 90 days of dialysis is likely to have resulted in un-
derestimation of the effect size of the associations. Third,
Medicare claims do not directly indicate which type of
vascular access is being used for dialysis. However, the
number of catheter insertions provides an indication of
catheter placement and general indication of catheter use.
The focus of our analysis was the effect of catheter inser-
tions on anemia management, not the effect of the type of
VA in use for dialysis. Fourth, no information was avail-
able regarding other potential confounding factors, such
as ferritin, transferrin saturation, parathyroid hormone,
C-reactive protein, and some oral medications. However,
these factors may influence baseline hemoglobin at initi-
ation of dialysis, and adjustment for baseline hemoglobin
may help to reduce potential confounding due to these
and other unavailable factors.
CONCLUSION
We found a direct association of higher numbers of
catheter insertions and VA infections with increased
rHuEPO requirements. Higher rHuEPO doses may be
required to maintain the same or slightly lower mean
hemoglobin values among chronic hemodialysis patients
with higher numbers of catheter insertions and VA in-
fections, compared to those without any. In the U.S., the
increasing use of dialysis catheters and the widespread
placement of PTFE grafts put hemodialysis patients at
high risk of serious VA-related infection. Implementation
2436 Roberts et al: Vascular access and anemia
of the NKF-K/DOQI Clinical Practice Guidelines for
Vascular Access may result in reduced infectious compli-
cations, rHuEPO requirements, and, consequently, cost
among patients undergoing chronic hemodialysis.
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